Chris March Appointed as Vice President of Human Resources at Supernus Pharmaceuticals, Inc.

Rockville, Maryland, United States, January 2025 – Chris March has been appointed as the Vice President of Human Resources at Supernus Pharmaceuticals, Inc. In this new role, he will lead the company’s strategic HR initiatives, focusing on talent management, employee engagement, and organizational development to support the company’s continued growth in the biopharmaceutical sector.

TARC Appoints Ajay Gupta as Chief Development Officer, Ankush Kaul as Chief Business Officer and Mridul Srivastava as Chief Human Resources Officer

Zoom appoints Carlos Quaderi as Head of APAC to drive next phase of AI-powered growth

Danielle Desrosiers Joins Damora Therapeutics as Head of Talent Acquisition

Chris March has been with Supernus Pharmaceuticals, Inc. for over three years, previously serving as the Executive Director of Human Resources, where he played a key role in overseeing HR operations, driving employee performance strategies, and supporting the company’s focus on the central nervous system (CNS) therapeutic space.

**Greatness is taken by every second organization, Now move to Happiness: Get Your Organization Happy Place to Work (HPTW) Certified**

Before joining Supernus, Chris was the Director of Human Resources at the Frederick National Laboratory for Cancer Research for approximately five years, where he managed HR operations for a 2,300-employee federally funded research facility. Earlier, he held the position of Head of Human Resources at Lonza, leading organizational development, talent acquisition, and employee relations.

His earlier career includes leadership roles at Knorr Brake Company, MedImmune, Randstad, BP Solar, and Corning Incorporated, contributing over two decades of expertise in HR leadership, strategic planning, and employee development.

About Supernus Pharmaceuticals, Inc.:
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of products for the treatment of central nervous system (CNS) diseases. The company leverages over 30 years of expertise in product development and markets key products, including Qelbree® for ADHD and Trokendi XR® for migraine and epilepsy treatment. Supernus continues to focus on expanding its CNS portfolio with promising candidates like SPN-812 and SPN-820.